Literature DB >> 11315066

Closed testing procedures for group sequential clinical trials with multiple endpoints.

D I Tang1, N L Geller.   

Abstract

A simple approach is given for conducting closed testing in clinical trials with multiple endpoints in which group sequential monitoring is planned. The approach allows a flexible stopping time; the earliest and latest stopping times are described. The paradigm is applicable both to clinical trials with multiple endpoints and to the one-sided multiple comparison problem of several treatments versus a control. The approach leads to enhancements of previous methods and suggestions for new methods. An example of a respiratory disease trial with four endpoints is given.

Entities:  

Mesh:

Year:  1999        PMID: 11315066     DOI: 10.1111/j.0006-341x.1999.01188.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  11 in total

1.  Testing a primary and a secondary endpoint in a group sequential design.

Authors:  Ajit C Tamhane; Cyrus R Mehta; Lingyun Liu
Journal:  Biometrics       Date:  2010-12       Impact factor: 2.571

2.  Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem.

Authors:  Peng Huang; Barbara C Tilley; Robert F Woolson; Stuart Lipsitz
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

3.  Longitudinal clinical trials with adaptive choice of follow-up time.

Authors:  Neal Jeffries; Nancy L Geller
Journal:  Biometrics       Date:  2015-03-27       Impact factor: 2.571

4.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

5.  A Rejection Principle for Sequential Tests of Multiple Hypotheses Controlling Familywise Error Rates.

Authors:  Jay Bartroff; Jinlin Song
Journal:  Scand Stat Theory Appl       Date:  2015-05-25       Impact factor: 1.396

6.  Combining censored and uncensored data in a U-statistic: design and sample size implications for cell therapy research.

Authors:  Lemuel A Moyé; Dejian Lai; Kaiyan Jing; Mary Sarah Baraniuk; Minjung Kwak; Marc S Penn; Colon O Wu
Journal:  Int J Biostat       Date:  2011-07-22       Impact factor: 0.968

7.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

8.  Using global statistical tests in long-term Parkinson's disease clinical trials.

Authors:  Peng Huang; Christopher G Goetz; Robert F Woolson; Barbara Tilley; Douglas Kerr; Yuko Palesch; Jordan Elm; Bernard Ravina; Kenneth J Bergmann; Karl Kieburtz
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

9.  Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial.

Authors:  Sheng Luo; Andrew B Lawson; Bo He; Jordan J Elm; Barbara C Tilley
Journal:  Stat Methods Med Res       Date:  2012-12-12       Impact factor: 3.021

10.  Adaptive choice of patient subgroup for comparing two treatments.

Authors:  Tze Leung Lai; Philip W Lavori; Olivia Yueh-Wen Liao
Journal:  Contemp Clin Trials       Date:  2014-09-07       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.